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Immunodeficiency and Chronic Myelogenous
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with a Targeted Mutation of the ICSBP Gene
Thomas Holtschke,1,7 Ju¨rgen Lo¨hler,2,7 regulatory factor (IRF) family (Maniatis et al., 1992). This
Yuka Kanno,3 Thomas Fehr,4 Nathalia Giese,5 family includes, in addition to ICSBP (Driggers et al.,
Frank Rosenbauer,6 Jing Lou,3 1992), IRF-1 (Miyamoto et al., 1988), IRF-2 (Harada et
Klaus-Peter Knobeloch,6 Lucia Gabriele,5 al., 1989), ISGF3g (Veals et al., 1992), and the more
Jeffrey F. Waring,1 Martin F. Bachmann,4 recently reported Pip (Eisenbeis et al., 1995) and IRF-3
Rolf M. Zinkernagel,4 Herbert C. Morse III,5 (Au et al., 1995). These proteins are composed of a
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University of Hamburg IFNb-regulated genes that are induced by viral infection
Hamburg (Maniatis et al., 1992). Type II IFN (IFNg), on the other
Federal Republic of Germany hand, regulates gene expression primarily through the
3Laboratory of Molecular Growth Regulation GAS element, to which Stat1 binds. Stat1 is a compo-
National Institute of Child Health nent of ISGF3 and is activated by both type I and type
and Human Development II IFNs through janus (JAK) kinases (Darnell et al., 1994).
National Institutes of Health There is extensive cross-talk between ISRE– and GAS–
Bethesda, Maryland 20205 mediated transcription, since ICSBP and IRF-1 are acti-
4 Institute of Experimental Immunology vated by IFNg, while Stat1 is activated by type I IFN in
University of Zu¨rich some cells (Kanno et al., 1993; Pine et al., 1994).
Zu¨rich In contrast to IRF-1 and IRF-2, which are expressed
Switzerland in most cells, ICSBP has been shown to be expressed
5Laboratory of Immunopathology exclusively in cellsof the immune system (Driggers et al.,
National Institute of Allergy and Infectious Diseases 1992). Recent studies show that ICSBP is constitutively
National Institutes of Health expressed throughout B cell ontogeny from early pro-B
Bethesda, Maryland 20205 cells to mature antibody-producing cells. While ICSBP
6Department of Molecular Genetics expression is very low in resting T cells and macro-
Research Institute of Molecular Pharmacology phages, its expression is strongly induced in these cells
Krahmerstrasse 6 upon immune stimulation and IFNg treatment. Previous
12207 Berlin studies have indicated that ICSBP has negative effects
Federal Republic of Germany on transcription of ISRE–carrying promoters (Nelson et
al., 1993, 1996). Furthermore, ICSBP has been shown
to complex with IRF-1 and IRF-2 as well as with Pu.1,
Summary a member of the Ets family of transcription factors selec-
tively expressed in hematolymphoid cells (Bovolenta et
Interferon consensus sequence binding protein al., 1994; Eisenbeis et al., 1995). In addition to the regula-
(ICSBP) is a transcription factor of the interferon (IFN) tion of IFN-responsive genes, IRF-1 and IRF-2 have been
regulatory factor (IRF) family. Mice with a null mutation shown to have antioncogenic/oncogenic properties
of ICSBP exhibit two prominent phenotypes related to (Harada et al., 1993). Surprisingly, however IRF-12/2 and
previously described activities of the IRF family. The IRF-22/2 mice do not exhibit gross pathological changes,
first is enhanced susceptibility to virus infections asso- although a thymocyte developmental defect was noted
ciated with impaired production of IFNg. The second in IRF-12/2 mice, and IRF-2–deficient animals exhibited
is deregulated hematopoiesis in both ICSBP2/2 and abnormalities of bone marrow hemopoiesis and B cell
ICSBP1/2 mice that manifests as a syndrome similar development (Matsuyama et al., 1993).
to human chronic myelogenous leukemia. The chronic To investigate the role of ICSBP in vivo, we generated
period of the disease progresses to a fatal blast crisis mice with a germline mutation of the ICSBP gene. Here,
characterized by a clonal expansion of undifferenti- we report that ICSBP–deficient mice have altered antivi-
ated cells. Normal mice injected with cells from mice ral responses and develop spontaneous disease syn-
in blast crisis developed acute leukemia within 6 dromes with similarities to human chronic myelogenous
weeks of transfer. These results suggest a novel role leukemia (CML). The results suggest that ICSBP, in addi-
for ICSBP in regulating the proliferation and differenti- tion to its role in control of IFN responses, is indispens-
ation of hematopoietic progenitor cells. able for the regulation of hemato- and lymphopoiesis.
Introduction Results
Interferon consensus sequence binding protein (ICSBP) Generation of ICSBP–Mutant Mice
is a transcription factor belonging to the interferon (IFN) The ICSBP gene was mutated by the targeted insertion
of a neomycin-resistance gene (PGK-neo) into the sec-
ond exon (Figure 1), which encompasses the major part7 These authors contributed equally to this work.
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Figure 2. The Absence of the ICSBP–IRF-2 Complex
(A) Electrophoretic mobility shift assay analysis of ISRE-binding ac-
tivity. Nuclear extracts (10mg of protein) from ICSBP1/1 and ICSBP2/2
spleens were tested for ISRE-binding activity using 32P-labeled
ISG15 probe (Bovolenta et al., 1994). Extracts were incubated with
preimmune rabbit serum (lanes 1 and 2), anti–ICSBP antibody (lanes
3 and 4), anti–IRF-2 antibody (lanes 5 and 6), and anti-ISGF3g anti-
body (lanes 7 and 8) for 15 min prior to the addition of the probe.
As a control, the same extracts were analyzed with a NFkB probe
(Kanno et al., 1993; lanes 9 and 10).
(B) Immunoblot analysis was performed for IRF-2 with 30 mg of
nuclear extracts, using rabbit anti–IRF-2 antibody as described (Nel-
son et al., 1996). Nuclear extracts from pre-B cells (70Z-3) and in
vitro translated IRF-2 were used as positive controls (right).
Northern blot analysis of poly(A)1RNA isolated from
spleens of ICSBP2/2 mice revealeda single ICSBP mRNA
species slightly shorter than that from ICSBP1/1 mice
(Figure 1). The sequence analysis of corresponding
Figure 1. Targeted Disruption of the ICSB Gene cDNA confirmed a short insert from the neo cassette
(A) Depicted is the organization of the wild-type ICSBP allele in gene and, as a result, the reading frame disruption by
relation to the targeting vector pPNS-icsbp. The relative positions multiple stop codons (data not shown). In agreement
of the exons are indicated. Closed boxes represent ICSBP coding
with these results, no ICSBP protein was detectedexons, thick lines represent intron sequences, and thin lines repre-
by immunoblot analysis of spleen cell extracts fromsent bacterial plasmid DNA. The untranslated region of exon 9, the
PGK-neo and tk- cassettes are shown as open boxes. Probes used ICSBP2/2 mice (Figure 1E). Also noted were the consis-
for Southern blot analysis are shown as closed bars. B, BamHI; S, tently lower levels of ICSBP protein in extracts from
SmaI. Diagnostic BamHI fragments: a recombinant band, 3.5 kb; a ICSBP1/2 mice as compared with those from ICSBP1/1
wild-type band, 5.0 kb.
mice, indicating a gene dosage effect of ICSBP expres-(B) Southern blot analysis of BamHI-digested tail DNA of F2-off-
sion. Predictably, IRF-1 and IRF-2 mRNA levels inspring. The DNA was hybridized with the probe A.
ICSBP2/2 spleen were similar to those found in control(C) Northern blot analysis shows splenic RNA (20 mg) hybridized
with labeled ICSBP, IRF-1, and IRF-2 cDNA probes (Kanno et al., mice (Figure 1D).
1993).
(D) Immunoblot analysis of ICSBP expression in spleens of mutant
Absence of the ICSBP–IRF-2 Complexmice. Whole cell extracts (40 mg) were separated on 10% SDS–
To examine whether ISRE–binding activity was alteredpolyacrylamide gel electrophoresis, and immunoblot analysis was
in ICSBP2/2 mice, we performed electrophoretic mobilityperformed using rabbit anti–ICSBP antibody (Bovolenta et al., 1994).
Baculovirus recombinant ICSBP (10 ng) was used as a control. shift assay analysis with nuclear extracts from spleen.
Levels of GAPDH (lower panel) in whole cellextracts were monitored There were five bands in control extracts, of which the
to ensure equal protein loading (Nelson et al., 1996). As expected, two upper bands were missing in extracts from the
no GAPDH immunoreactivity was present in the recombinant ICSBP
ICSBP2/2 spleen (Figure 2A, lanes 1 and 2). In vivo, ICSBPpreparation (right lane).
occurs as a complex with IRF-2 (Nelson et al., 1996),
which is represented by the uppermost band that was
supershifted by anti–ICSBP antibody (lane 3). However,of the DNA-binding domain. ICSBP–mutant mice were
derived as described in Experimental Procedures. Prog- no supershifted band was detected in extracts from the
ICSBP2/2 spleen (lane 4), consistent with the absenceeny of crosses from mice heterozygous for the mutation
yielded the expected proportions of genotypes. of the ICSBP protein in ICSBP2/2 spleen cells. Anti–IRF-2
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antibody supershifted the two uppermost bands in con- (CD41 and CD81 T cells) or increased 2-fold or more (B
cells) owing to the proportionate increases in spleentrol extracts (lane 5), which consisted of, first, the
ICSBP–IRF-2 complex and second, IRF-2. However, size and cellularity. In lymph nodes, the frequency of B
cells was significantly increased, and the proportion ofanti–IRF-2 antibody did not supershift a band in
ICSBP2/2 extracts (lane 6), indicating that IRF-2 expres- mature B cells with the phenotype of plasmablasts
(B220dull, CD431) in both spleen and lymph node wassion is deficient in ICSBP2/2 mice. As seen in the immu-
noblot analysis (Figure 2B), the IRF-2 protein was not augmented relative to that of small resting cells. Corre-
spondingly, increased levels of serum Ig were detecteddetected in ICSBP2/2 spleen extracts, consistent with
the absence of IRF-2 binding. Anti–ISGF3g antibody, (data not shown). The population of CD51 B cells in the
peritoneal cavity was not detectably expanded (data notused as a control, did not supershift a band in extracts
from either ICSBP2/2 or wild-type mice (Figure 2A, lanes shown). For ICSBP–deficient mice, the organization and
cellular composition of the thymus were essentially nor-7 and 8). A control probe containing the binding site for
NFkB produced a similar binding pattern with extracts mal, with both immature CD41CD81 and mature single
positive CD41CD82 and CD42CD81 cells present in nor-from both ICSBP1/1 and 2/2 mice, confirming the specific
abrogation of the ICSBP–IRF-2 complex in the ICSBP2/2 mal frequencies (data not shown). This indicates that
early T cell development and selection is grossly normalmice.
Our data suggest that IRF-2 protein expression is re- in mice lacking ICSBP.
The ability of T cells or NK cells to produce IFNgduced in ICSBP2/2 spleen (Figure 2B), the basis of which
is currently under study. The fact that a considerable was examined following stimulation of spleen cells with
ConA or lipopolysaccharide (LPS; Figure 3B). IFNg pro-amount of IRF-2 mRNA was detected in ICSBP2/2 spleen
suggests a defect in posttranscriptional/translational duction in response to ConA was reduced more than
3-fold in ICSBP2/2 mice 1–5 months of age, while IFNgmodifications of IRF-2. It has been shown previously
that enhanced C-terminal cleavage of IRF-2 occurs in production in response to LPS was reduced more than
100-fold compared with ICSBP1/1 mice; indeed, re-virus-infected cells (Palombella and Maniatis, 1992).
sponses were below the limits of detection in 9 of 12
ICSBP2/2 mice. RT–PCR analyses of constitutive IFNgExpression of IFN–Regulated Genes
Since IFNa and IFNb genes carry the ISRE in their pro- transcripts showed them to be reduced about 3-fold in
spleens of ICSBP2/2 as compared with wild-type animalsmoters and their expression is regulated by the IRF
family proteins, we performed reverse transcriptase– (Figure 3C). For ICSBP2/2 mice, the levels of IFNg protein
induced by ConA and the steady-state levels of tran-polymerase chain reaction (RT–PCR) analysis for ex-
pression of these genes in spleen, lymph nodes, and scripts for IFNg are in keeping with the reduced relative
frequencies of T cells in spleen and suggest that IFNgbone marrow. Constitutive IFNa and IFNb mRNA levels
were not grossly altered in ICSBP2/2 tissues (data not expression by T cells is normal.
Expression of IFNg following activation of spleen cellsshown). Furthermore, although ICSBP is known to affect
activity of MHC class I and b2-microglobulin promoters with LPS is induced by IL-12 produced primarily by mac-
rophages and monocytes and, to a lesser extent, B cells(Nelson et al., 1993), no significant alterations were de-
tected in their mRNA levels or the surface expression and neutrophils. The possibility that decreased IFNg
expression in ICSBP2/2 mice following LPS stimulationof MHC class I on ICSBP2/2 lymphoid cells (data not
shown). could be due to altered regulation by IL-12 was sug-
gested by the observation that transcripts for the p40In addition, we observed that spleen cells from
ICSBP2/2 mice respond to both IFNa and IFNg in vitro chain of this cytokine were markedly reduced in spleens
of mutant mice, while expression of IL-12 p35 transcriptsby activating ISGF3g and Stat1, indicating that the path-
ways for JAK/Stat and JAK/ISGF3g are not abrogated was normal (Figure 3B). The deficiency in IL-12 p40
expression is quite striking considering the increasedin ICSBP2/2 spleen cells (data not shown).
frequencies of macrophages and monocytes in spleens
of mutant mice.Immune System and Cytokine Expression
of ICSBP2/2 Mice
To determine whether hematopoietic development is
Antiviral Immune Responsesaffected by the absence of ICSBP, we compared spleen,
Immune responses of ICSBP2/2 mice to three differentbone marrow, lymph node, and thymus cells for expres-
viruses were analyzed. ICSBP2/2 mice survived and weresion of cell lineage markers by flow cytometric analyses
able to produce normal neutralizing antibody titers to(Figure 3).
vesicular stomatitis virus (VSV), suggesting that the BThe most striking finding was markedly increased fre-
and T helper cell compartment as well as the IFN typequencies of granulocytes (GR-11/Mac-11) and, to a
I system were normal in these mice (data not shown).lesser extent, macrophages (GR-12/Mac-11) in spleen,
However, when ICSBP2/2 mice were infected with vac-lymph node, and bone marrow (Figure 3A). Markedly
cinia virus (VV) or lymphocytic choriomeningitis virusincreased frequencies of granulocytes were also de-
(LCMV) at a dose that was well controlled by normaltected in peripheral blood (see below). The frequencies
littermates, 80% of VV–infected and 100% of the miceof granulocytes in spleen and nodes of homozygous
infected with the slowly and restrictedly replicatingdeficient mice were found to increase with age.
LCMV strain Armstrong died within 10–20 days (FiguresAlthough the relative frequencies of B cells and T cell
4C and 4G). Analysis of cytotoxic T lymphocyte (CTL)subsets were decreased in spleen (Figure 3A), the total
numbers of lymphocyte subsets were either normal responses after VSV (Figure 4A, secondary restimulation
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Figure 3. Immunologic Features of ICSBP2/2 Mice
(A) Single cell suspension from spleen, bone marrow, lymph node, and thymus of ICSBP–deficient mice (2/2) and their wild-type littermates
(1/1) were stained with indicated combinations of antibodies for flow cytometric studies. Numbers in the quadrants indicate the percent
among total cells in the quadrant. Analyses were of 11-week-old mice and are representative of five pairs of 1/1 and 2/2 mice tested at
10–16 weeks of age. For mice in this age range, the weights and total cellularity of ICSBP2/2 spleens were increased 3- to 5-fold over controls,
and lymph node size and cellularity were increased 2- to 3-fold over normal.
(B) ConA- and LPS-induced IFNg expression by spleen cells was determined by enzyme-linked immunosorbent assay. Results indicate the
mean plus or minus standard error for assays of 10 1/1 and 12 2/2 mice.
(C) RTR–PCR analyses of constitutive IFNg, IL-12p35, IL-12p40, and HPRT transcripts in spleen cells of ICSBP–deficient (2/2) and wild-type
littermate controls (1/1).
d33) and VV infection (Figure 4B, primary response d6) with wild-type littermates, they developed with a 100%
penetrance signs of a hematologic neoplasia with a re-revealed a 3- to 10-fold reduction of CTL activity. These
data suggested an enhanced virus replication in the semblance to CML in humans. Macroscopically, the
most prominent alteration was a systemic lymphade-early phase, which then could not be controlled by the
later developing specific CTL responses. To test this, nopathy and hepatosplenomegaly. The enlarged lymph
nodes were colonized by neutrophilic granulocytes (Fig-we infected ICSBP2/2 mice with 200 pfu of the rapidly
and widely replicating LCMV strain WE. While infection ure 5A), predominantly mature neutrophils intermingled
with juvenile and myelocytic forms. Paracortical andinto the footpad was well controlled by the virtually nor-
mal CTL responses (Figure 4D), intravenous infection medullary plasma cell hyperplasia, at least temporarily,
also contributes to lymph node enlargement. Pseudo-caused death of about 40% of the animals (Figure 4G);
this was most likely due to immunopathology, as docu- Gaucher cells phagocytosing granulocytic and other he-
matopoietic cells were abundant (Figure 5B). Themented by CD81 T cell–mediated hepatitis (Figure 4H;
Zinkernagel et al., 1986). The other 60% survived owing plasma cells were chiefly of the IgG isotype and dis-
played cytomorphological anomalities usually encoun-to exhaustion of the specific CTL response (Moskoph-
idis et al., 1993) and uninhibited growth of LCMV-WE. tered in plasmacytomas (Figure 5C). The progressive
expansion of myeloid, histiocytic, and B-lymphoid cellsThis was shown by markedly reduced primary and ab-
sence of secondary CTL responses (Figures 4E and 4F) leads finally to complete effacement of lymph node ar-
chitecture.and persisting virus in liver (1 3 105 pfu), spleen (7 3
106 pfu), and kidney (8 3 105 pfu) 40 days after infection. In mice, in contrast to humans, the spleen is a hemato-
poietic as well as a lymphoid organ. In ICSBP2/2 mice,
a progressive expansion of the red pulp was seen withCML–like Disease
Although young ICSBP2/2 mice showed no difference in increasing age comprising the same cell types observed
in the lymph nodes of the mutant mice. In addition,size, behavior, and reproductive ability as compared
Myelogenous Leukemia in ICSBP–Deficient Mice
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Figure 4. Antiviral Immune Responses of
ICSBP2/2 Mice
(A and B, D–F) Mice were infected with the
respective viruses on day 0, and primary ex
vivo or secondary in vitro (after 5 days of re-
stimulation) activity of CTLs was determined
in Cr-release assay on peptide-loaded (VSV
and LCMV) or virus-infected (VV) target cells.
E/T ratio, effector to target cell ratio; i.v., intra-
venously; i.f., into the footpad.Open symbols:
ICSBP1/1 mice; closed symbols: ICSBP2/2
mice; circles: peptide-pulsed or virus-in-
fected target cells; triangles: unlabeled target
cells. Each line represents one mouse. One
of two comparable experiments of each type
is shown.
(C and G) Mice were infected with 2 3 106
pfu of VV (C, n 5 11) or 2 3 102 pfu of the LCMV
isolatesWE orArm (G,n 5 7or 6,respectively),
and survival was monitored during the indi-
cated time periods. Open symbols: ICSBP1/1
mice; closed symbols: ICSBP2/2 mice.
(H) Mice were infected with 200 pfu of LCMV-
WE on day 0 with or without prior in vivo
depletion of CD81 T cells, and the occurence
of hepatitis was monitored by determination
of liver enzyme activity in serum on the indi-
cated timepoints. Closed symbols: glutamate
oxalacetate aminotransferase (GOT); open
symbols: glutamate pyruvate aminotransfer-
ase (GPT) activity.
erythropoiesis was greatly increased, and there was a was invaded by myeloid cells. Involvement of liver char-
marked proliferation of abnormal megakaryocytes. acterized by extensive periportal and sinusoidal inva-
Myeloproliferative alterations of bone marrow and sion by mature and immature granulocytes and pseudo-
lymphoid tissues precede changes in the composition Gaucher cells, similar to leukemic liver infiltration in
of blood leukocytes for a long time. Only whenthe spleen humans, is an invariant characteristic of ICSBP–defi-
has tripled its normal size can a significant shift towards cient animals, as is the granulocytic and plasma cell
the granulocytic lineage be recorded. Examination of infiltration of myocardium, lungs, and kidneys. A moder-
blood films of ICSBP2/2 mutants with fully developed ate numerical increase of hypertrophic mast cells is seen
myeloproliferative disease, which is associated with in the loose connective tissue. In the small intestine there
moderately elevated leukocyte numbers, revealed left- is a striking hyperplasia of lymphocytes and plasmacells
shifted neutrophilia (Table 1). Morphologically, the white in Peyer’s patches and the lamina propria. In summary,
blood cells at this disease stage appeared mostly nor- the hematologic alterations in ICSBP2/2 mice are mainly
mal (Figure 5D). characterized by hyperproliferation of abnormal my-
The bone marrow of ICSBP2/2 mice exhibited a eloid, histiocytic, and lymphocytic cells, which in some
marked hypercellularity due to an increase of mature aspects simulates the chronic phase of CML in humans.
granulocytes and their precursors (Table 1; Figure 5E) Similar hematopathologic alterations, although in a
intermingled with numerous pseudo-Gaucher cells. The quantitatively reduced form, were observed also in
frequencies of lymphocytes and plasma cells were re-
ICSBP1/2 mice (data not shown).
duced. The erythroid compartment was greatly de-
creased, and megakaryocytes were atypical and with
Fatal Blastic Leukemiaadvanced disease reduced numerically. Evolution of fi-
Transition of the chronic form to fatal blast crisis is abrosis was not observed, but, consistently, the connec-
tive tissue of the periosteum and adjoining musculature characteristic feature of human CML. Approximately
Cell
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Figure 5. Hematopathology of ICSBP2/2
Mice
(A) Enlarged peripheral lymph node with re-
sidual cortical follicle and germinal center on
the left side. Paracortex and medulla are
densely populated with neutrophils, eosino-
philic pseudo-Gaucher cells, and plasma-
blasts (hematoxylin–eosin, 3 100).
(B) Pseudo-Gaucher cells in lymph node ex-
hibit intracellular storage of crystaloid, eosin-
ophilic material, and hemophagocytosis. No-
tice absence of lymphocytes; instead, many
granulocytes and some plasma cells are
present (hematoxylin–eosin, 3 530).
(C) Hypertrophic atypical plasma cells of
lymph node medulla (IgG immunostaining, 3
400).
(D) Blood film of ICSBP–deficient mouse
showing neutrophilic leukocytosis (Pappen-
heim stain, 3 400).
(E) Bone marrow smear demonstrating in-
crease of granulopoiesis while erythropoiesis
is absent. A pseudo-Gaucher cell is seen in
the lower left corner (Pappenheim stain, 3
400).
(F) Granulocytic sarcoma of lymph node dur-
ing blast cell crisis consisting of relatively uni-
form medium-sized myeloid blast cells
(Giemsa stain, 3 530).
(G) Leukemic infiltration of kidney during blast
cell crisis. Most of the tumor cells stain posi-
tive (red) by myeloperoxidase immunostain-
ing (3 500).
(H) Blood film depicting severe leukocytosis
composed of myeloid and lymphoid blast
cells besides atypical monocytoid cells and
some normal lymphocytes and neutrophils
(Pappenheim stain, 3 825).
33% of ICSBP2/2 and 9% of ICSBP1/2 mice became Macroscopically, the changed course of disease pro-
cess is characterized by striking lymphadenopathy andmoribund by 50 weeks of age (Figure 6A); all moribund
mice had features indicating a transition to a blast crisis. hepatosplenomegaly (spleen weight 500–2000 mg) and
Table 1. Hematological Parameters of CML-like Disease (Chronic Stage) in ICSBP–Deficient Mice
Peripheral blood Bone marrow
ICSBP 1/1b 2/2c 1/1d 2/2e
Percent of cellsa
netrophil segments 11.75 6 1.8 58.0 6 6.5  29.02 6 3.61 58.1 6 3.26netrophil bands 0.25 6 0.25 1.17 6 0.79
metamyelocytes ,0.03 1.0 6 0.69 2.9 6 0.6 7.95 6 1.59
myelocytes 8.34 6 0.84 7.65 6 0.45
promyelocytes ,0.03 0.14 6 0.14 3.37 6 0.5 6.77 6 0.33
myeloblasts 1.1 6 0.13 5.9 6 0.21
eosinophils 2.5 6 0.63 1.43 6 0.37 3.55 6 0.7 1.52 6 0.13
lymphocytes 84.5 6 1.66 28.71 6 4.16  25.37 6 1.79 7.19 6 2.19lymphoblasts ,0.03 0.71 6 0.29
nuclear erythroid cells ,0.03 ,0.03 25.14 6 2.31 4.38 6 1.1
megakaryocytes ,0.03 ,0.03 0.42 6 0.14 ,0.05
monocytes 1.25 6 0.48 2.43 6 1.48 1.19 6 0.28 1.39 6 0.38
leukocytes/ml 3 103 6.76 6 0.55 38.9 6 9.5
erythrocytes/ml 3 106 8.65 6 0.71 7.89 6 0.48
platelets/ml 3 105 9.22 6 0.75 12.30 6 1.07
a Differential cell counts were performed by identifying at least 300 cells per peripheral blood smear and 500 cells per marrow smear. Numbers
are given as means plus or minus standard error.
b n 5 4, c n 5 7, d n 5 3, e n 5 3
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Figure 6. Fatal Blastic Leukemia
(A) Mortality of ICSBP2/2 (circles), ICSBP1/2
(closed squares), and ICSBP1/1 (open
squares) mice.
(B) FACS analysis of cells from 1/1 and 2/2
mice from chronic and acute stage of dis-
ease. Lymph node cellls were stained with
indicated combinations of antibodies and an-
alyzed as described in Experimental Proce-
dures. The ages of the mice were 36 weeks
for the 1/1 and 25 and 22 weeks for the 2/2
mice in chronic or acute stage, respectively.
The weights and total cellularity of 2/2 lymph
nodes were increased 5-fold over control for
the chronic stage and 18 times over control
for the acute stage.
(C) Clonal expansion of leukemic cells. South-
ern blot hybridization for the organization of
IgJH genes using JH probe. DNA prepared
from the spleen of a 10-month-old ICSBP2/2
mouse in blastic stage (lane 1) or two recipi-
ents of spleen cells (lane 2) or lymph node
cells (lane 3) from another ICSBP2/2 mice in
blastic stage.
(D) Determination of the genotype of tumor
cells in ICSBP1/1 mice transplanted with cells
from ICSBP2/2 mice in blastic stage. DNA
samples from tissues of a leukemic recipient
(lanes 2, 3, 4, and 6) and control ICSBP1/1 (lane 1) and ICSBP2/2 (lane 5) mice were analyzed by PCR using primers described in Experimental
Procedures. Tissues of a leukemic recipient: ear (lane 2), spleen (lane 3), solid tumor (lane 4), liver (lane 6).
additionally by a marked enlargement, distortion, and neutrophils, 4.5% erythroid cells, 4.1% lymphoid cells,
0.9% eosinophils, and 1.6% Gaucher-like cells or sea-greenish-white hue of all abdominal organs, including
the intestinal and urogenital tracts. On microscopic in- blue histiocytes.
spection, the organ lesions are characterized by a dif-
fuse uniform infiltrate of medium-sized or blast cells (see Transplanted Leukemias
To test the leukemogenicity of cells from both chronicFigure 5F) focally intermingled with some myeloid and
histiocytic cells of different maturational stages and, in stage and blast crisis, 1 3 106 cells were injected intrave-
nously into nonirradiated ICSBP1/1 mice. As shown inthe case of lymph node tumors, with residual lympho-
cytes. Sometimes eosinophils are interspersed among Table 2, 15of 16mice injected with cells from two mice in
blast crisis developed progressively growing leukemiasthe blast cells. Although the blast cells with their round
or, less frequently, irregular nuclei and scantycytoplasm within 6–11 weeks of transplantation. By contrast, only
1 of 62 mice injected with cells from 10 mice in themimic lymphoblastic or mixed cell lymphomas, their
staining for myeloperoxidase (Figure 5G), chloroacetate chronic phase of disease developed a leukemia of donor
origin.esterase, lysozyme, and immunoglobulins revealed that
most of them belong to the granulocytic lineage; but The transplanted cells developed in the hematopoi-
etic, lymphoid, and parenchymal organs of their hostsareas of histiocytic and lymphocytic differentiation are
also present. These findings in the nonhematopoietic into the same kind of leukemia and widespread granulo-
cytic sarcomas with mixed differentiation as in thetissues are equivalent to what in human blast cell crisis
is designated as granulocytic sarcoma or chloroma. He- ICSBP2/2 donors with blast crisis. Accordingly, in all
diseased recipient animals with granulocytic sarcomas,matologically, this stage of the disease is characterized
by leukocyte counts of over 100,000 per ml with a blast Pappenheim-stained bone marrow smears consisted
exclusively of 50% small atypical lymphoid cells andprevalence of about 10% and a prevalence of atypical
neutrophils of about 14%, while lymphoid cells ac- 50% small to medium-sized blasts, a portion of which
exhibited some myeloid differentiation (azurophiliccounted for about 76% (Figure 5H). Immunostaining of
blood films revealed that only half of the blasts were granules). In the periphery, the leukemic blood (greater
than 100,000 leukocytes per ml) contained 12.1% blastMac-11, indicating a bi- or tri-phenotypic nature of the
blast transformation. Expansion of both granulocytic cells, atypical promyelocytes, and myelocytes, 7.6%
atypical neutrophils, and 79.8% lymphoid cells. Expres-and B-lymphoid cells has also been documented by
fluorescence-activated cell sorter (FACS) analyses (Fig- sion of leukocyte markers was in a representative case
49% Ia1(B cells), 31% Mac-11 (myeloid and monocyticure 6B). Histologically, the bone marrow is populated
by a relatively uniform mass of blasts and immature cells), and 11% Thy-11 (T cells).
Southern blot analyses of immunoglobulin heavymyeloid cells eroding the bone and invading and replac-
ing the adjoining musculature. A typical myelogram con- chain gene JH organization showed the transplanted
cells to be clonal (Figure 6C). Furthermore, the origin ofsists of 30.4% greatly abnormal myeloblasts, promyelo-
cytes, myelocytes, and metamyelocytes, 58.5% atypical leukemic clones from donor mice was confirmed by
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Table 2. Transplantable Leukemias
Disease-stage Number of Observation time Number of recipients
of donors Donor organ Number of donors recipients (weeks) with leukemia
chronic sp 6 28 11–12 1
chronic bm 4 34 11–23 0
blast crisis sp 2a 10 6–11 9
blast crisis bm 1a 3 6 3
blast crisis ln 1a 3 6 3
Nonirradiated ICSBP1/1 mice were injected i.v. with 106 cells from lymphoid organs of ICSBP2/2 mice. Mice were scored for the development
of leukemia by blood smears. Abbreviations: sp, spleen; bm, bone marrow; ln, lymph nodes.
a The same mouse was used as a donor.
PCR analyses revealing the presence of 547 bp band members of the IRF family may be critical determinants
of IL-12 expression and thus may influence productiondiagnostic of ICSBP2/2 cells (Figure 6D).
of IFNg as well as the balance of CD41 T helper 1 to TThe possibility that ecotropic retroviral insertional mu-
helper 2 function in immune responses to a variety oftagenesis might be involved in the genesis of the leuke-
pathogens (Trinchieri, 1995).mias is ruled out by two observations. First, mice with
Induction of IFNg appears critical for resolving thesethe ICSBP mutation bred onto the 129 genetic back-
infections, and ICSBP2/2 mice aredeficient inproductionground, which lacks endogenous ecotropic virus, de-
of this cytokine following stimulation of T cells by cross-velop changes like those seen on the (129 3 C57BL/6)
linking of the T cell receptor (TCR) or B cells and macro-mixed genetic background. Second, neither germline
phages with LPS. The way in which ICSBP regulatesnor acquired clonal ecotropic proviral integrations were
expression of the IFNg gene is not known, but directdetected by Southern blot analyses of the DNAs from
effects on gene transcription are unlikely, since an ISREleukemia transplants found to have clonal JH re-
or a similar element has not been identified in the regula-arrangements (data not shown).
tory regions of the gene. The role of ICSBP in IFNg
regulation is more likely indirect and could reflect theDiscussion
influences of ICSBP on IL-12 or other elements of the
cytokine network, which may be perturbed in ICSBP2/2The above results reveal two main features of ICSBP–
mice.deficient mice. They are more susceptible to certain
A further indication of an impaired immune system isvirus infections, and they develop a myelolymphoproli-
a high susceptibility of ICSBP2/2 mice kept in a conven-ferative disease with similarities to human CML. These
tional facility to opportunistic infections, which fre-findings suggest that ICSBP plays two distinct roles:
quently manifest as chronic purulent skin ulcerationsfirst, as a prominent regulator of antiviral immune re-
and pseudotumorous botryomycosis (data not shown).sponses, and second, as a critical growth determinant
of hematopoietic cells.
The Role of ICSBP in Early
Hematolymphoid Progenitors
Immunodeficiency A central conclusion to be drawn from these studies is
The humoral arm of the antiviral response to VSV was that ICSBP–deficient mice exhibit enhanced prolifera-
found to be intact, indicating relatively normal T helper tion of myeloid, monocytic, lymphoid, and perhaps meg-
cell–B cell interactions. Dramatically enhanced viral rep- akaryocytic lineages, suggesting that the decisive alter-
lication in the early phase of infection, probably due to an ation occurs in an early common progenitor cell. Effects
IFNg–dependent defect in innate immunity, overhelmed of the ICSBP mutation were evident already by day 17 of
the reduced but still sufficient CTL responses. The out- embryogenesis (data not shown), supporting the notion
come was death due to virus-induced tissue destruction that the defect is not caused by environmental factors
in the case of cytopathic VV or changed quality of immu- but by an alteration in the developmental potential of a
nopathology in the case of the restrictedly replicating stem cell common to these lineages.
noncytopathic variant (Arm) of LCMV. For VSV and pe- Development of hematolymphoid cells from pluripo-
ripheral infections with LCMV-WE, the phenotype of tent stem cells proceeds through a tightly controlled
ICSBP2/2 mice corresponds to IFN type II receptor-defi- process of differentiation and proliferation of immature
cient mice (Huang et al., 1993); for systemic infection lineage-committed progenitors into fully mature cells.
with LCMV-WE, the phenotype with viral persistence On the molecular level, this control is exercised by net-
is intermediate between IFN types I and II receptor- works of extracellular and intracellular signaling path-
deficient mice (Mu¨ller et al., 1994). Similarly impaired ways, whichregulate expression of specific target genes
antiviral immunity was seen previously in IRF-2– (for review see Metcalf, 1989; Weissman, 1994). Re-
deficient mice, which died within 30 days of intravenous cently, several transcription factors essential for hema-
infection with LCMV (Arm), a challenge survived nor- topoietic development such as Tal-1, Rbtn-2, GATA-1
mally by IRF-1–deficient and normal mice (Matsuyama and 2, Pu.1, and others were identified by targeted muta-
et al., 1993). genesis. The exact in vivo role for most of these factors
The marked reduction in transcripts for IL-12(p40) and their target genes, however, remains to be eluci-
dated (for review see Shivdasani and Orkin, 1996).suggests that ICSBP and its interactions with other
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ICSBP seems to regulate negatively a critical growth- 1994). The notion that IFN regulates proliferation of he-
matopoietic cells has been substantiated by Hwang etcontrol gene and could thus be a tumor suppressor.
This is not surprising in view of the described oncogenic/ al. (1995), who found elevated levels of myeloid lineage
cells in peripheral blood and bone marrow of IFNa-antioncogenic activity of other IRF genes (Harada et al.,
1993). Furthermore, a monocytic cell line transfected receptor deficient mice. Thus, it is not entirely surprising
that the disruption of ICSBP gene connected with anwith a dominant negative form of ICSBP exhibited al-
tered growth (Thornton et al., 1996; our unpublished alteration of IFN signaling is manifested by an enhanced
cell proliferation. It is conceivable that the absence ofdata).
Changes in the normal pattern of cytokine signaling ICSBP (and IRF-2) leads to a disequilibrium of IRF and
IRF–interacting proteins (STATs, Pu.1) with a conse-would be an obvious explanation for the hematopoietic
abnormalities seen in ICSBP–deficient mice. For exam- quent formation of different protein complexes that in
turn activate other target genes. Taken together, theple, it has been shown that overexpression of IL-3, IL-6,
or GM-CSF can cause myeloproliferation in mice (Wong data suggest that the balance between proliferative
(growth factors) and antiproliferative (IFN) signals iset al., 1989; Hawley et al., 1992; Johnson et al., 1989).
In ICSBP2/2 mutants, semiquantitative RT–PCRanalyses maintained by interactions of STAT and IRF factors.
Similar to human CML, ICSBP2/2 and, with a lowerdo not reveal substantial (greater than 3-fold) differ-
ences in expression of splenic transcripts for IL-1, IL-2, frequency, ICSBP1/2 mice transit from a chronic stage
to acute blast crisis characterized by clonal expansionIL-3, IL-4, IL-5, IL-6, IL-10, IL-12(p35), IFNa1, IFNb,
TNFa, G-CSF, GM-CSF, or LIF (data not shown). of leukemic cells. Prolonged cell survival allowing time
for additional mutations in other oncogenes is the mostHowever, transcripts for several cytokine receptors,
G-CSFR, GM-CSFR, and M-CSFR, were reduced in likely mechanism toexplain transition of chronic to acute
blastic leukemia (Rabbitts, 1991, 1994). It would be inter-granulocytes of ICSBP2/2 as compared with wild-type
mice (data not shown). The importance of these quanti- esting to study whether the same gene alterations as
those described in humans are involved also in thetative changes to the alterations in myelopoiesis ob-
served in ICSBP2/2 mice is not yet known. ICSBP leukemia.
The results shown argue for an essential role of ICSBPNevertheless, the fact that we have not observed any
dramatic changes in cytokine expression, except for in the differentiation of hematolymphoid cells. However,
the mechanisms leading to leukemic transformation, theIFNg and IL-12, does not exclude the possibility that
cytokine signaling pathways could be altered in signaling intermediates and target genes that are dereg-
ulated in ICSBP–deficient mice, remain to be deter-ICSBP2/2 mice.
mined. The ICSBP–deficient mice should be a valuable
tool to study the signaling pathways that control normal
CML–like Disease and malignant proliferation of hematolymphoid cells.
The major characteristic features of human CML (first,
a chronic period of disease with predominantly granulo-
Experimental Procedurescytic involvement; second, transition into a fatal blast
crisis with the clonal expansion of undifferentiated cells;
Targeting Vector
and third, the involvement of several cell lineages indica- To generate the targeting vector, phage clones containing ICSBP
tive of a defect in an early common progenitor)are invari- genomic sequences were isolated from a mouse BALB/c DNA library
ably found in the murine disease as well. (Driggers et al., 1992). The clone used encompasses the second
exon and first and second intron of ICSBP gene. The PGK-neoThe molecular hallmark of CML is the presence of an
cassette (Rudnicki et al., 1992) was introduced in the sense orienta-activated bcr–abl tyrosine kinase resulting from a t(9;22)
tion into the unique SmaI site of the second exon. The PGK-tkchromosomal translocation originally identified as the
cassette was introduced into ScaI site 39 of the homologous ICSBP
Philadelphia chromosome. Several mouse model sys- sequence. The final targeting vector pPNS-icsbp contains 4.0 of
tems involving expression of the bcr–abl fusion protein ICSBP homology and can be linearized by PvuI.
have demonstrated a causal relationship with the devel-
opment of myeloid and lymphoid malignancies (re-
Transfection of Embryonic Stem Cellsviewed by Sawyers et al., 1991). Multiple downstream
and Blastocyst Injection
targets of the bcr–abl or abl are suggested by different Linearized pPNAS-icsbp DNA (1.5 mg) was electroporated into E14.1
studies that include ras as well as Jak/STAT signaling embryonic stem cells (Schorle et al., 1991), and embryonic stem–cell
clones were grown under double selection as described (Rudnicki(Danial et al., 1995; Carlesso et al., 1996). Analyses of
et al., 1992). DNA of individual double-resistant clones was cut withabl mRNA expression and the genomic organization of
BamHI and probed with A and B probes. The screening strategyc-abl in ICSBP2/2 mice did not reveal any differences as
and probes are shown in Figure 1. Homologous recombinant clonescompared with control mice (data not shown). Neverthe-
demonstrated a 3.5 kb recombinant band, in addition to a 5.0 kb
less, the striking similarity between the murine and hu- wild-type band in Southern blots. Alternatively, PCR analysis was
man disorders provokes speculations on a common de- employed to distinquish the mutated and wild-type allele. The
sequences of the three primers are: first, 59-CATGGCACTGGTCCfect downstream of the bcr–abl signaling pathway.
AGATGTCTTCC-39; second, 59-CTTCCAGGGGATACGGAACATGApproximately 75% of patients in chronic stage of
GTC-39; and third, 59-CGAAGGAGCAAAGCTGCTATTGGCC-39.CML achieve hematologic remission after IFNa therapy.
Positive clones were expanded and injected into C57BL/6 blasto-It has been previously discussed that IFN might counter-
cysts. Resulting chimeric animals were crossed to both C57BL/6
act the enhanced proliferation of leukemic cells by and 129/Ola mice. Germline transmission was identified by Southern
blocking the signaling pathways of growth factors, thus blotting, and brother–sister mating was carried out to generate
ICSBP2/2 mice. Mice were kept in barrier facilities.allowing normal maturation to continue (Gutterman,
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Electrophoretic Mobility Shift Assay (Serotec), Gr-1, and ER-MP (Pharmingen). As secondary overlays,
biotin-conjugated F(ab’)2 fragments of immunoaffinity-purifiedand Immunoblot Analysis
Nuclear extracts were prepared according to Antalis and Godbolt sheep anti-rabbit IgG (Sigma), rabbit anti-goat IgG, or goat anti-
rat IgG (Dianova) were employed and subsequently detected with(1991), with a modified lysis buffer that contained 10 mM Tris (pH
7.5), 10 mM NaCl, 15 mM MgCl2, 0.05% NP40, and protease inhibi- streptavidin-biotinylated peroxidase complexes (DAKO) or “super-
sensitive” streptavidin-alkaline phosphatase conjugate (Biogenex).tors (Boehringer Manheim). Reactions for electrophoretic mobility
shift assay were performed as described (Kanno et al., 1993), using Peroxidase activity was revealed with H2O2 and 3,3-diaminobenzi-
dine-tetrahydrochloride (Fluka).10 mg of nuclear extract. The ISRE probe was from the ISG15 gene
(Bovolenta et al., 1994), and the NFkB probe was from the Igk gene.
Cell Transfers
Immunologic Procedures Cells from organs of donor mice were suspended, washed, and
Samples from tissues were frozen at 2708C in RNAzol for later injected intravenously into tails of 2–6-month-old recipient mice
processing in RT–PCR analyses, and single cell suspensions were (C57BL/6 3 129/Ola) F1 mice. Mice were monitored twice a week
prepared from lymphoid organs for tissue culture and FACS analy- and were killed for histopathologic studies and collection of tissues
ses. Cells were stained with monoclonal antibodies (MAbs) prepared for mRNA and DNA analyses when moribund.
in our laboratory or purchased from Pharmingen, labeled with FITC,
phycoerythrin, or biotin. The biotin-labeled antibodies were de- Acknowledgments
tected using avidin coupled to FITC, phycoerythrin, or allophycocy-
anin. The MAbs included those to CD4, CD5, CD8, CD11b (Mac-1), We thank S. Chattopadhyay for help with clonality assay and H.
CD32, CD45R(B220), CD54(ICAM-1), MHC class I H-2Kb, MHC class Haber, K. Heigl, Y. Kim, N. Nelson, and A. Peters for technical assis-
II I-Ab, TCRa/b, and GR-1. Viable cells gated by narrow forward- tance. These studies were supported by grants from the Deutsche
angle light scatter and exclusion of propidium iodide were analyzed Forschungsgemeinschaft (SFB 465) and the Sander-Stiftung to I. H.
on a FACScan or a FACS Vantage (Becton Dickinson) using Cell- and by Human Science Frontier Program Strassburg and the Swiss
quest software. National Science Foundation to R. M. Z. The Heinrich-Pette-Institute
In studies of IFNg induction, cells were cultured in 1 ml volumes is supported by Freie und Hansestadt Hamburg and Bundesminist-
in 24 well plates at 5 3 106 cells/ml. Supernatants were harvested erium fu¨r Gesundheit, Bonn. J. W. was supported by A. von Hum-
at 24–72 hr after stimulation with ConA (5 mg/ml), LPS (50 mg/ml), boldt Foundation and L. G. in part by the AIDS Italian National
and plate-bound anti–TCRa/b monoclonal antibody (300 ng/well), Project. Correspondence should be sent to I. H. (fax: 1149-30-
and assayed for IFNg levels using an enzyme-linked immunosorbent 8445-3803).
assay as previously described (Gazzinelli et al., 1993).
The primers, probes, and methods for preparation of RNA, cDNA, Received April 22, 1996; revised August 9, 1996.
and amplification of cytokine transcripts were as previously de-
scribed (Giese et al., 1996).
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